Your session is about to expire
← Back to Search
Deferiprone Therapy for Heart Attack (MIRON-DFP Trial)
MIRON-DFP Trial Summary
This trial tests if a drug can reduce iron in the heart of people who had a heart attack, to help them recover.
MIRON-DFP Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowMIRON-DFP Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.MIRON-DFP Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My body weight is over 309 lbs.My liver enzymes are high, and I'm not on chronic liver disease medication.My doctor expects I have less than 1 year to live due to a non-heart related condition.I have a history of heart attack or heart surgery.My heart's pumping ability is below 40%.I am allergic to gadolinium/contrast agents.My kidney function is severely reduced.I have a condition like hemochromatosis or thalassemia, or I am being treated with iron chelators.I had a specific type of heart attack affecting the front wall of my heart, confirmed by symptoms, ECG changes, and high heart markers.
- Group 1: Hemorrhagic Myocardial Infarction - Deferiprone
- Group 2: Non-hemorrhagic Myocardial Infarction - Deferiprone
- Group 3: Hemorrhagic Myocardial Infarction - Placebo
- Group 4: Non-hemorrhagic Myocardial Infarction - Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Who is eligible to participate in this scientific experimentation?
"This clinical trial is seeking sixty participants aged 18 to 75 who have experienced myocardial infarction. Criteria for inclusion are manifesting symptoms of myocardial ischemia, including chest pain and shortness of breath; elevated biomarkers (Troponin); coronary angiogram with primary PCI regardless of the length of time since onset; and new or presumed new ST-segment elevation on ECG at 0.2 mV in leads V1, V2, V3 or V4, and 0.1 mV in other leads."
How many individuals are actively enrolled in this clinical investigation?
"Affirmative. According to the findings on clinicaltrials.gov, this medical experiment is currently recruiting participants, which commenced posting on November 1st 2022 and was recently updated on November 2nd 2022. The team needs 60 patients from a single site."
Are participants still eligible to join this experiment?
"According to the information accessible on clinicaltrials.gov, this medical experiment is actively searching for participants, with initial posting of November 1st 2022 and most recent update being made on November 2nd 2022."
Could you provide an assessment of the risks of Non-hemorrhagic Myocardial Infarction - Deferiprone for patients?
"Due to the limited data on safety and efficacy, Non-hemorrhagic Myocardial Infarction - Deferiprone received a score of 1."
Does this medical trial accept individuals who are of legal age?
"Per the eligibility criteria, individuals aged 18 to 75 are suitable for this trial. Additionally, there are 11 trials designed specifically for minors and 357 clinical studies dedicated to seniors."
Share this study with friends
Copy Link
Messenger